Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04927364
Other study ID # 54988
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 6, 2022
Est. completion date November 2023

Study information

Verified date July 2023
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to evaluate the efficacy of deep transcranial magnetic stimulation (dTMS) as a treatment for Veterans with an alcohol use disorder (AUD).


Description:

At least 60% of those with AUD will experience a major relapse period within 6 months of treatment, irrespective of the intervention (psychosocial and/or pharmacological) employed. Consequently, the high prevalence of AUD and relapse following treatment in Veterans is associated with substantial resource allocation and costs for the VA Health Care System. Current pharmacological and psychosocial interventions demonstrate only a moderate level of efficacy, which is reflected in the high rate of relapse in AUD. TMS is a neurostimulation method that is at the forefront of innovative, non-invasive, and safe treatments for AUD, and other psychiatric disorders. To reduce the high rate of relapse in Veterans with AUD, it is necessary for interventions to more effectively address the associated neurobiological dysfunction. Non-invasive neuromodulation techniques are showing promise toward the aim of modifying specific and selective neural targets related to AUD and relapse. However, device-based interventions to date for AUD have focused on cortical stimulation. In contrast, preclinical and clinical studies, including our research team's preliminary data, suggest that subcortical nodes within the salience network could be promising novel neuromodulation targets. The dorsal anterior cingulate cortex (dACC) is a core node of the salience network, and hence the target of this proposal. Deep repetitive transcranial magnetic stimulation (dTMS) is one type of neuromodulation technique, and utilizing an H7 coil design can reach the dACC. Monitoring periodically throughout the first 6 months following treatment is crucial, given relapse within the first 6 months of treatment is robustly related to poor psychosocial functioning over the ensuing 1-3 years. The ultimate goal of this proposal is to provide treatment that more effectively promotes sustained abstinence in the Veteran with AUD, as extended abstinence is robustly associated with optimum biomedical, neuropsychological, psychiatric, and psychosocial recovery and functioning.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10
Est. completion date November 2023
Est. primary completion date May 17, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 70 Years
Eligibility Inclusion Criteria: - The study will be open to male and females, regardless of race and ethnic origin, 21-70 years of age, who are in active treatment for an AUD at the VAPAHCS, Foundations of Recovery. - Participants must meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for AUD, and alcohol is self-identified as the primary substance of misuse. - Able to read, verbalize understanding, and voluntarily sign the Informed Consent Form prior to participation in study procedures in English. - Participants will be accepted if taking medications specifically for the treatment of major depressive disorders, cigarette smoking, or for other psychiatric conditions as long as the medications are not documented to lower seizure threshold - it would be clinically contraindicated to require participants to discontinue such medications for research. rTMS is safely administered to individuals who are taking psychotropic medications that do not lower seizure threshold. - Participants will be abstinent from alcohol and non-prescribed substances for at least 7 consecutive days prior to rTMS to ensure no participant is experiencing active acute withdrawal. Exclusion Criteria: Psychiatric: - Current diagnosis of Schizophrenia Spectrum Disorders and Bipolar Disorders; - Current moderate-severe substance use disorder other than alcohol, tobacco, or marijuana, based on DSM-5 diagnostic criteria; - Active current suicidal intent or plan (patients with a previous clinical flag for risk for suicide will be required to have an established safety plan involving their primary psychiatrist and the treatment team before entering the clinical trial, any form of previous rTMS or electroconvulsive treatment) Biomedical: Including, but not limited to: - Uncontrolled thyroid disease, - Unstable congestive heart failure, - Angina - Other severe cardiac illness as defined by treatment regimen changes in the prior 3 months - Cerebrovascular accident, cancer if < 1 year since end of treatment; - Unstable diabetes - COPD requiring oxygen supplementation - Alzheimer's disease - Parkinson's disease - Any biomedical implants with ferromagnetic content, neurostimulation devices, cardiac pacemakers or any magnetic resonance contraindications; - Traumatic brain injury with self-reported or observed loss of consciousness > 30 minutes, any primary or traumatically induced seizure disorder, and alcohol-related seizure(s) in the past 30 days. General: - Lack of fluency in English; - Wechsler Adult Reading Test below the 7th percentile (i.e., moderate or greater impairment in estimated general intelligence); - Females who are pregnant or actively attempting pregnancy; - Conservative exclusion for magnetic resonance research, current use of any medication or substance that is documented to lower seizure threshold or has been identified as a contraindication for rTMS treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Deep Transcranial Magnetic Stimulation (dTMS) H7 coil
The study will utilize the H7 coil to administer Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.

Locations

Country Name City State
United States VA Palo Alto Health Care System Palo Alto California

Sponsors (2)

Lead Sponsor Collaborator
Stanford University VA Palo Alto Health Care System

Country where clinical trial is conducted

United States, 

References & Publications (3)

Harel M, Perini I, Kampe R, Alyagon U, Shalev H, Besser I, Sommer WH, Heilig M, Zangen A. Repetitive Transcranial Magnetic Stimulation in Alcohol Dependence: A Randomized, Double-Blind, Sham-Controlled Proof-of-Concept Trial Targeting the Medial Prefrontal and Anterior Cingulate Cortices. Biol Psychiatry. 2022 Jun 15;91(12):1061-1069. doi: 10.1016/j.biopsych.2021.11.020. Epub 2021 Dec 6. — View Citation

Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010 Jan;35(1):217-38. doi: 10.1038/npp.2009.110. Erratum In: Neuropsychopharmacology. 2010 Mar;35(4):1051. — View Citation

Peters SK, Dunlop K, Downar J. Cortico-Striatal-Thalamic Loop Circuits of the Salience Network: A Central Pathway in Psychiatric Disease and Treatment. Front Syst Neurosci. 2016 Dec 27;10:104. doi: 10.3389/fnsys.2016.00104. eCollection 2016. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Relapse to alcohol 6months after treatment Six months after completing the intervention, participants will be contacted to determine self-reported relapse status. Participants will complete brief standardized measures of alcohol and substance use, Alcohol Timeline Followback (TLFB) and the Brief Addiction Monitor (BAM) questionnaire. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05973019 - rTMS Improves Functions in Spinocerebellar Ataxia N/A
Recruiting NCT06193278 - Individual Neuromodulation for PDS N/A
Completed NCT05074524 - Repetitive Transcranial Magnetic Stimulation to Reduce Heroin Cravings N/A
Recruiting NCT05889117 - Brain Stimulation for Concussion N/A
Recruiting NCT03974659 - Enhanced Recovery After Surgery Using TMS on Cerebellar Language Area for Brain Tumor Patients N/A
Recruiting NCT05613686 - Theta Burst Stimulation for Motor Recovery N/A
Completed NCT04014491 - The Effects of Exercise Training on Corticospinal System in Overhead Athletes With Shoulder Impingement Syndrome N/A
Recruiting NCT05914038 - Individualized rTMS for Motor Recovery in Stroke Patients N/A
Recruiting NCT06084455 - TMS-evoked Potentials During Aerobic Exercise N/A
Completed NCT05566444 - TMS-evoked Potentials During Heat Pain N/A
Enrolling by invitation NCT04313530 - TMS Treatment in Multiple System Atrophy With Fatigue N/A
Completed NCT04209309 - Repetitive Transcranial Magnetic Stimulation as a Potential Tool to Reduce Sexual Arousal N/A
Terminated NCT04486222 - Accelerated Bilateral rTMS on Geriatric Depression N/A
Recruiting NCT05192759 - Effect of Theta-Burst Transcranial Magnetic Stimulation (TBS) for Freezing of Gait N/A
Recruiting NCT05467657 - Transcranial Magnetic Stimulation on Somtosensory Cortex Enhances Motor Learning in People With Stroke N/A
Recruiting NCT05896332 - rTMS in Older Adults With MCI and AUD Phase 1
Recruiting NCT04727177 - Precision-targeted Transcranial Magnetic Stimulation in the Treatment of Primary Dystonia Early Phase 1
Recruiting NCT04906603 - Theta Burst Stimulation for Headaches After Traumatic Brain Injury N/A
Recruiting NCT03590327 - Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment N/A
Recruiting NCT05843240 - Effects of Repetitive Transcranial Magnetic Stimulation on Cerebral Autoregulation in Patients With Acute Ischemic Stroke N/A